Non-Fucosylated Anti-Human CCR5 (PRO140) Therapeutic Antibody (CAT#: BioBet-944ZP) Datasheet

CCR5

C-C chemokine receptor type 5

CCR5, CC-CKR-5, CCCKR5, CCR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22, C-C motif chemokine receptor 5

Plasma membrane

Diseases associated with CCR5 include West Nile Virus and Diabetes Mellitus, Insulin-Dependent, 22.

Its related pathways are Signaling by GPCR and AKT Siganaling Pathway.

Many inflammatory cc chemokines of the receptor, including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES, then transduce signals by increasing intracellular calcium levels. May play a role in controlling the proliferation or differentiation of the granulocyte lineage. (Microbial infection) is the co-receptor of human immunodeficiency virus-1/HIV-1 (CD4 is the main receptor).

Sulfated on at least 2 of the N-terminal tyrosines. Sulfation contributes to the efficiency of HIV-1 entry and is required for efficient binding of the chemokines, CCL3 and CCL4. O-glycosylated, but not N-glycosylated. Ser-6 appears to be the major site. Also sialylated glycans present which contribute to chemokine binding. Thr-16 and Ser-17 may also be glycosylated and, if so, with small moieties such as a T-antigen. Palmitoylation in the C-terminal is important for cell surface expression, and to a lesser extent, for HIV entry. Phosphorylation on serine residues in the C-terminal is stimulated by binding CC chemokines especially by APO-RANTES.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

PRO140

Human

Human

The antibody targeting GPCR are implicated in a wide variety of diseases such as rheumatoid arthritis and Crohn disease, as well as metabolic disease and cancer.

Cancer

Cancer